Semiconductor Ultrasound
A medical device company repositioning as a chip platform — licensing its Ultrasound-on-Chip technology to partners building things Butterfly would never build itself.
Personal notes published for reference. Figures are sourced from company filings, releases, and press coverage as of the date above — the interpretation is mine and may be wrong.
CEO Joe DeVivo, CFO John Doherty, with David Horsley (SVP Innovation) on the technology side. The strategic call that matters is DeVivo's: recognizing the chip was worth more as a licensable platform than as a component in Butterfly's own handheld probes. That reframing is the entire current thesis.
This is the part that changed. Point-of-care ultrasound is a real but bounded market. Butterfly Embedded — the licensing and co-development arm — opens the chip to any third party building ultrasound-enabled hardware, in and beyond healthcare. The TAM stops being 'handheld probes sold' and becomes 'devices containing our silicon.'
The weak criterion. Butterfly has struggled financially as a standalone hardware seller and continues to post losses. Licensing revenue is high-margin and contractually visible, but it is small relative to the cost base today. This is not yet a cash-flow story.
Two Embedded partners went public with working hardware within a week of each other in June 2026 — the first external proof the platform strategy produces something other than press releases.
Butterfly proved its Ultrasound-on-Chip technology in point-of-care imaging with the iQ series, now on its third generation. Butterfly Embedded (formerly Octiv) licenses that same semiconductor platform to third parties.
Selling probes means competing on distribution, regulatory clearance, and sales headcount in a mature medical device market. Selling chips and licenses means collecting fees and per-unit revenue while someone else takes the commercialization risk. The margin profile and the capital intensity are not comparable — and the addressable market is set by other people's imagination rather than Butterfly's product roadmap.
The generative-AI company signed a five-year co-development and licensing agreement in November 2025, then revealed what it was building in June 2026: Midjourney Medical and the Midjourney Scanner, a full-body ultrasonic computational tomography device.
$15M one-time fee, $10M annual license fee paid quarterly across the five-year term, up to $9M in milestone payments, plus revenue sharing on hardware incorporating Butterfly chips and separate payments for the chip purchases themselves. Exclusive within a specified field of use.
Midjourney is targeting 5,000 “Midjourney Spas” at roughly 10 scanners each, with a first San Francisco location expected late 2027 and next-generation scanners in 2028. At ~40 chips per scanner, 50,000 units implies chip volumes on a completely different order than the probe business. Butterfly has said later versions may use more modules, not fewer.
Shares jumped sharply on the June reveal — reported moves of 31% to 56% depending on the window — to a 52-week high around $8. The stock then gave a chunk back, which is worth remembering: the reaction priced in a rollout that has barely started.
The scanner is an early-stage prototype, not a cleared medical device. FDA approval would be required for medical use; initial applications focus on body-composition mapping. William Blair flagged open questions on how this actually plays out. The $74M ceiling is a ceiling, not a forecast.
A research lab building non-invasive brain interfaces, and the second Embedded partner to go public with results — a week after Midjourney.
In June 2026 Aleph announced what it describes as the highest-resolution 3D images of the human brain ever captured from outside the skull, using Butterfly's Ultrasound-on-Chip platform — framed as “MRI-level detail” without drilling or an MRI machine's bulk.
Founded by CEO Marley Xiong with co-founders Raffi Hotter and Lev Chizhov. Early-stage, and explicitly a research lab rather than a commercial product company — so there is no near-term revenue attached.
Two independent partners, two completely different applications — full-body tomography and brain-computer interfaces — from the same silicon, within eight days. That's the strongest available evidence that Embedded is a genuine platform rather than one bespoke deal. Brain interfaces are also a category where the ceiling is nowhere in sight.
Butterfly's upside now runs through other companies' execution. Midjourney's spa rollout, FDA pathways, and Aleph's research all sit outside Butterfly's control.
First Midjourney location late 2027, next-gen scanners 2028, 50,000 units by 2031. The meaningful chip volume is years out; the stock has already moved on it.
The handheld probe business still loses money. Compass AI and Butterfly Garden are attempts to build higher-margin software revenue around it, but the base business needs to stop bleeding regardless of what Embedded does.
This is a small cap that moved 30–56% on a single partner announcement and 19% down in another session. Headline-driven in both directions.